Menopause is a critical window for women's cardiovascular health — but big questions remain. Hormone loss during menopause raises risks for stroke, heart attack, and kidney disease, yet no trials have proven that hormone therapy improves heart outcomes. Experts are calling for modern randomized trials to finally give women and their doctors clear answers.
Menopause isn't just a reproductive milestone — it's a major turning point for a woman's heart health. At the Heart in Diabetes CME Conference, Dr. Martha Gulati of Houston Methodist highlighted how the loss of estrogen during menopause triggers widespread changes across the body, affecting blood pressure, cholesterol, insulin resistance, and inflammation, all of which elevate the risk of stroke, heart attack, coronary artery disease, and chronic kidney disease.
Despite growing patient interest in menopausal hormone therapy (MHT), the evidence base remains thin. No large randomized controlled trials with hard cardiovascular endpoints exist for contemporary MHT formulations. Current guidance suggests MHT may be safe for symptomatic women at low CVD risk — but it is not recommended for primary CVD prevention.
Key Takeaways:
Why it matters: With millions of women navigating menopause and asking their doctors about hormone therapy, the lack of robust trial data leaves a critical gap. Experts are urging investment in contemporary randomized controlled trials to deliver the evidence women and clinicians urgently need.
